Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuat...
Saved in:
Main Authors: | Tatsuya Nagano, Yoshikazu Kotani, Kazuyuki Kobayashi, Masahiro Katsurada, Yukihisa Hatakeyama, Suya Hori, Daisuke Tamura, Daisuke Kasai, Yasuhiro Funada, Yoshihiro Nishimura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Case Reports in Pulmonology |
Online Access: | http://dx.doi.org/10.1155/2011/812972 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Busting the Breast Cancer with AstraZeneca’s Gefitinib
by: S. Chemmalar, et al.
Published: (2023-01-01) -
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer
by: Puwei Song, et al.
Published: (2023-01-01) -
Correction: AlRasheed et al. Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats. <i>Pharmaceuticals</i> 2022, <i>15</i>, 1400
by: Hajer AlRasheed, et al.
Published: (2024-12-01) -
Anti-cancer activity of synthetic gefitinib-1,2,3-triazole derivatives against Hela cells via induction of apoptosis
by: Zhihong Hu, et al.
Published: (2025-01-01) -
The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib
by: Jing Zhang, et al.
Published: (2025-01-01)